Trade Cabaletta Bio, Inc. - CABA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0322 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.2589 |
| Open | 1.2189 |
| 1-Year Change | -90.57% |
| Day's Range | 1.2189 - 1.2889 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 1.2589 | -0.0700 | -5.27% | 1.3289 | 1.3489 | 1.2489 |
| Apr 23, 2025 | 1.3289 | 0.0300 | 2.31% | 1.2989 | 1.3689 | 1.2989 |
| Apr 22, 2025 | 1.2589 | 0.1300 | 11.52% | 1.1289 | 1.2889 | 1.1289 |
| Apr 21, 2025 | 1.1589 | 0.0900 | 8.42% | 1.0689 | 1.1789 | 1.0589 |
| Apr 17, 2025 | 1.0989 | 0.0500 | 4.77% | 1.0489 | 1.1189 | 1.0489 |
| Apr 16, 2025 | 1.0689 | -0.0500 | -4.47% | 1.1189 | 1.1189 | 1.0489 |
| Apr 15, 2025 | 1.1089 | -0.0300 | -2.63% | 1.1389 | 1.1789 | 1.0989 |
| Apr 14, 2025 | 1.1489 | -0.1000 | -8.01% | 1.2489 | 1.2489 | 1.0889 |
| Apr 11, 2025 | 1.2089 | 0.1200 | 11.02% | 1.0889 | 1.2389 | 1.0789 |
| Apr 10, 2025 | 1.0789 | 0.0100 | 0.94% | 1.0689 | 1.0989 | 1.0289 |
| Apr 9, 2025 | 1.1089 | 0.0800 | 7.78% | 1.0289 | 1.1689 | 1.0089 |
| Apr 8, 2025 | 1.0189 | -0.1800 | -15.01% | 1.1989 | 1.1989 | 1.0189 |
| Apr 7, 2025 | 1.1289 | 0.0800 | 7.63% | 1.0489 | 1.1689 | 0.9690 |
| Apr 4, 2025 | 1.0889 | -0.0400 | -3.54% | 1.1289 | 1.1589 | 1.0689 |
| Apr 3, 2025 | 1.1789 | 0.0200 | 1.73% | 1.1589 | 1.2089 | 1.1289 |
| Apr 2, 2025 | 1.2189 | 0.0600 | 5.18% | 1.1589 | 1.2489 | 1.1489 |
| Apr 1, 2025 | 1.1489 | -0.2200 | -16.07% | 1.3689 | 1.3689 | 1.1489 |
| Mar 31, 2025 | 1.3689 | -0.1200 | -8.06% | 1.4889 | 1.4889 | 1.3489 |
| Mar 28, 2025 | 1.5389 | -0.0300 | -1.91% | 1.5689 | 1.5989 | 1.4789 |
| Mar 27, 2025 | 1.5889 | 0.0200 | 1.27% | 1.5689 | 1.6589 | 1.5489 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cabaletta Bio, Inc. Company profile
About Cabaletta Bio Inc
Cabaletta Bio Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cabaletta Bio Inc revenues was not reported. Net loss increased 39% to $46.3M. Higher net loss reflects Research and development increase of 53% to $29.7M (expense), Stock-based Compensation in R&D increase of 38% to $2.7M (expense), General and administrative increase of 7% to $10.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.44 to -$1.80.
| Industry: | Bio Therapeutic Drugs |
2929 Arch Street
Suite 600
PHILADELPHIA
PENNSYLVANIA 19104
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com